Y.D. More Investments Ltd Sells 168,568 Shares of Kamada Ltd. (NASDAQ:KMDA)

Key Points

• Y.D. More Investments Ltd has reduced its stake in Kamada Ltd. by 33.8%, selling 168,568 shares, resulting in ownership of 330,354 shares valued at approximately $2.18 million.
• Several institutional investors have altered their positions, including Huntleigh Advisors Inc. and NewEdge Advisors LLC, indicating increased interest in Kamada's stock.
• Kamada's stock has a current price of $7.01 with a market capitalization of $403.15 million, and the company recently reported earnings meeting analysts' expectations with $0.07 EPS.

Y.D. More Investments Ltd lowered its holdings in Kamada Ltd. (NASDAQ:KMDA - Free Report) by 33.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 330,354 shares of the biotechnology company's stock after selling 168,568 shares during the quarter. Y.D. More Investments Ltd owned about 0.57% of Kamada worth $2,181,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of KMDA. Huntleigh Advisors Inc. bought a new position in shares of Kamada in the first quarter valued at $863,000. NewEdge Advisors LLC raised its holdings in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after acquiring an additional 8,260 shares during the last quarter. Geode Capital Management LLC lifted its position in Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after acquiring an additional 1,549 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Kamada in the 4th quarter valued at about $67,000. Institutional investors own 20.38% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on KMDA. Sidoti raised Kamada to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen upgraded Kamada from a "buy" rating to a "strong-buy" rating in a report on Wednesday, May 21st. Finally, Benchmark reissued a "buy" rating and issued a $15.00 price target on shares of Kamada in a research report on Thursday, May 15th.

Kamada Stock Performance

Shares of KMDA stock opened at $7.01 on Thursday. The company has a market capitalization of $403.15 million, a price-to-earnings ratio of 24.17, a PEG ratio of 0.83 and a beta of 0.93. Kamada Ltd. has a 52-week low of $5.17 and a 52-week high of $9.15. The company has a 50-day simple moving average of $7.39 and a two-hundred day simple moving average of $7.05.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, hitting analysts' consensus estimates of $0.07. The firm had revenue of $44.02 million for the quarter, compared to the consensus estimate of $154.06 million. Kamada had a return on equity of 6.31% and a net margin of 9.60%. On average, sell-side analysts forecast that Kamada Ltd. will post 0.23 EPS for the current fiscal year.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

Want to see what other hedge funds are holding KMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kamada Ltd. (NASDAQ:KMDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.